HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HBW Market Roundup: Homeopathic Guidance Comments, Clif Bar Packages, ABC Awards, ZBiotics Funding

Executive Summary

FDA extends deadline through 23 May for comments on draft guidance for homeopathic industry oversight; Clif Bar changes character on packaging for the first time in 28 years to honor female athletes; ABC announces Duke, Kronenberg and Champion awards; and probiotics firm ZBiotics raised funding for additional development.

You may also be interested in...



HBW Regulatory News: Canadian OTC Firm Warned On GMPs, Homeopathic Guidance Comment Extended

FDA says Apollo Health And Beauty Care isn't meeting GMP requirements; and comment period on FDA draft guidance for oversight of homeopathic industry extended through March 23.

Wellness Market Product Launches: Rejuvant, USANA, ZBiotics, Comvita Kids, Knosh, 7-Eleven, ERApeutics

USANA adds probiotics in oral care, launches menopause supplement; ZBiotics probiotics engineered for hangovers; Comvita launches Manuka honey children's cough/cold drops; Knosh supplements for sleep, mood and energy; 7-Eleven competes in energy drinks sector; ERApeutics has walnut milk for brain health; and Rejuvant LifeTabs for longer 'healthspan.'

Biohaven Relaunches As Biohaven Ltd. After Pfizer Buyout Closes

As signaled when Pfizer acquired Biohaven’s Nurtec and CGRP assets, Biohaven will continue under a modified name, with a focus on epilepsy, obsessive compulsive disorder and spinal muscular atrophy.

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS149795

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel